Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17810785 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL16095317 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL29398446 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL30564433 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL118970 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL30510331 | 1.00 | TLR2 (0.42) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL25179514 | 0.97 | TLR2 (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL30792938 | 0.97 | TLR2 (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL25182297 | 0.97 | TLR2 (0.43) | TLR2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL24633752 | 0.95 | TLR2 (0.45) | TLR2KMT2AFABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | UNIV EMORY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| US-9700881-B2 | Heterocyclic coupling catalysts and methods related thereto | EMORY UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2017070157-A1 | REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2015054337-A1 | HETEROCYCLIC COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885KMT2A 3145/4885FABP5 4094/4885 |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | HAT1, CBR3, CBR1 | TLR2 4500/4885KMT2A 608/4885FABP5 3026/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | TLR2 3191/4885KMT2A 1822/4885FABP5 4703/4885 |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SELENOI | TLR2 4036/4885KMT2A 926/4885FABP5 3722/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | TLR2 4611/4885KMT2A 4757/4885FABP5 4026/4885 |
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | CD274, PDCD1, PDCD1LG2 | TLR2 575/4885KMT2A 2643/4885FABP5 1197/4885 |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SQOR | TLR2 3925/4885KMT2A 1054/4885FABP5 3712/4885 |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | TLR2 575/4885KMT2A 2643/4885FABP5 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.